Eurizon Capital SGR S.p.A. Acquires Shares of 69,188 Labcorp Holdings Inc. $LH

Eurizon Capital SGR S.p.A. acquired a new stake in Labcorp Holdings Inc. (NYSE:LH) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 69,188 shares of the medical research company’s stock, valued at approximately $17,361,000.

Several other institutional investors also recently bought and sold shares of the company. Hantz Financial Services Inc. increased its stake in Labcorp by 48.8% in the 3rd quarter. Hantz Financial Services Inc. now owns 122 shares of the medical research company’s stock valued at $35,000 after buying an additional 40 shares during the period. Advisor OS LLC grew its stake in shares of Labcorp by 5.4% during the 3rd quarter. Advisor OS LLC now owns 821 shares of the medical research company’s stock worth $236,000 after purchasing an additional 42 shares during the period. Pinnacle Associates Ltd. grew its stake in shares of Labcorp by 3.9% during the 4th quarter. Pinnacle Associates Ltd. now owns 1,126 shares of the medical research company’s stock worth $282,000 after purchasing an additional 42 shares during the period. Larson Financial Group LLC grew its stake in shares of Labcorp by 37.5% during the 3rd quarter. Larson Financial Group LLC now owns 154 shares of the medical research company’s stock worth $44,000 after purchasing an additional 42 shares during the period. Finally, Cary Street Partners Investment Advisory LLC grew its stake in shares of Labcorp by 7.6% during the 4th quarter. Cary Street Partners Investment Advisory LLC now owns 668 shares of the medical research company’s stock worth $168,000 after purchasing an additional 47 shares during the period. 95.94% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Labcorp

In related news, CEO Adam H. Schechter sold 5,903 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $254.50, for a total value of $1,502,313.50. Following the sale, the chief executive officer directly owned 107,234 shares in the company, valued at $27,291,053. The trade was a 5.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.84% of the stock is owned by corporate insiders.

Labcorp Stock Performance

NYSE:LH opened at $260.21 on Monday. Labcorp Holdings Inc. has a fifty-two week low of $241.81 and a fifty-two week high of $293.72. The company has a quick ratio of 1.54, a current ratio of 1.73 and a debt-to-equity ratio of 0.68. The firm’s fifty day simple moving average is $263.22 and its 200-day simple moving average is $265.87. The stock has a market cap of $21.34 billion, a PE ratio of 23.05, a price-to-earnings-growth ratio of 1.82 and a beta of 0.90.

Labcorp (NYSE:LH) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $4.25 EPS for the quarter, topping the consensus estimate of $4.09 by $0.16. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The business had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.51 billion. During the same period in the previous year, the firm earned $3.84 EPS. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. Analysts expect that Labcorp Holdings Inc. will post 17.99 earnings per share for the current fiscal year.

Labcorp Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 11th. Investors of record on Friday, May 29th will be given a $0.72 dividend. The ex-dividend date is Friday, May 29th. This represents a $2.88 annualized dividend and a dividend yield of 1.1%. Labcorp’s payout ratio is currently 25.51%.

Wall Street Analyst Weigh In

LH has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. upped their price target on shares of Labcorp from $319.00 to $330.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. Wall Street Zen raised shares of Labcorp from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Robert W. Baird set a $334.00 price target on shares of Labcorp in a research note on Friday, May 1st. Morgan Stanley reaffirmed an “overweight” rating on shares of Labcorp in a research note on Tuesday, February 17th. Finally, Piper Sandler upped their price target on shares of Labcorp from $270.00 to $300.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 24th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $308.00.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.